Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

LIFESTYLE

  • FDA Greenlights Sanofi's Qfitlia for Hemophilia—An Innovative Alternative to Daily Injections FDA approves Sanofi's Qfitlia for hemophilia, offering bimonthly injections and significant bleeding reduction at $642K annually.
  • Prostate Cancer Screenings May Cut Death Risk in Half, Study Finds Prostate cancer screening can cut mortality rates by 50%, highlighting the need for early detection through PSA testing among high-risk men.
  • It’s Not Just Depression: Personality Disorders Linked to Highest Suicide Risk Schizophrenia may surpass depression in suicide risk; personality disorders significantly elevate this risk, highlighting urgent treatment needs.
  • Faster Cancer Treatment? Merck Launch Set for Subcutaneous Keytruda Rollout Merck plans to launch a subcutaneous Keytruda for cancer treatment in the US, awaiting FDA approval by September 23.
  • Cutting Carbs? You Might Be Raising Your Risk of Colon Cancer New research reveals low-carb diets may increase colon cancer risk due to harmful gut bacteria and lack of fiber.
  • Tired of the Buzz? Fruit and Dairy Might Help, New Study Says A study suggests that increased intake of fruits, dairy, caffeine, and fiber may lower tinnitus risk among individuals.
  • Study Finds Missing Gut Bacteria in Parkinson’s and IBD Patients New research links inflammatory bowel disease to Parkinson's disease, revealing reduced beneficial gut bacteria in affected patients.
  • New Research Reveals Ketogenic Diet Slows Biological Aging by 6+ Years A study finds the ketogenic diet may slow epigenetic aging by over six years, highlighting its potential for health and weight management.
  • New Drug Cuts Heart Disease Risk by 94%—And Has No Major Side Effects Eli Lilly's Lepodisiran shows a 93.9% reduction in lipoprotein levels, a key heart disease risk factor, in mid-stage trials.
  • Wegovy Maker Strikes $1B Deal for Next-Gen Obesity Treatment Novo Nordisk acquires global rights to Lexicon's obesity drug LX9851, aiming to enhance its position in the obesity treatment market.
  • This Celebrity Lost 7kg—and Her Diet Includes ... ChoA shares her healthy lunch featuring fruits and peanut butter, highlighting its nutritional benefits and her recent weight loss.
  • Red vs. White Wine: Which Is Riskier for Cancer? New Study Has the Answer A study shows no significant difference in cancer risk between red and white wine, though white wine may increase skin cancer risk.
  • Breakfast vs. Dinner: Which Meal Should You Load Up On for Better Health? A hearty breakfast aids weight control, stabilizes blood sugar, and supports heart health, while big dinners can harm well-being.
  • Eat More Greens—But Skip the Fake Stuff, Scientists Warn A plant-based diet rich in whole foods can extend lifespan, especially for those with diabetes or heart disease, while processed snacks can harm health.
  • Veggies vs. IBD: New Research Says the Right Diet Might Be a Game-Changer A nutrient-rich, plant-based diet may lower inflammatory bowel disease risk, while junk food plant diets increase it.
  • Eli Lilly Moves First in India, Beats Novo in Obesity Drug Showdown Eli Lilly launches Mounjaro in India, targeting a large market and competing with Novo Nordisk's Wegovy for obesity treatment.
  • Trump’s Soda Button and 12-Can Habit: A Recipe for Trouble? Trump's eating habits, including fast food and soda, contrast with Biden's healthier choices, impacting their health and weight.
  • New FDA-Approved Pill Targets Constant Hunger in Children with PWS FDA approves Soleno's Vykat XR for treating hyperphagia in Prader-Willi Syndrome, aiming to improve patients' quality of life.
  • Too Much Exercise Might Not Help You Live Longer, Says New Study A study questions the belief that high physical activity significantly extends lifespan, suggesting moderate activity may be sufficient.
  • Novo Nordisk Just Bought the Next Big Thing in Weight Loss Novo Nordisk secures global rights to Triple-G weight loss therapy through a licensing deal, targeting three hormones for better results.
1 2 3 4 5 6 7 8 9 10 91